MedTrace Logo

Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

NCT01661491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-11-13

No results posted yet for this study

Summary

Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.

Conditions

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Barbara I Kazmierczak, MD PhD · Yale University

  • Marie Egan, MD · Yale University

Eligibility

Min Age
3 Months
Max Age
4 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01661491 on ClinicalTrials.gov